Modulation Effect of Peroxisome Proliferator-Activated Receptor Agonists on Lipid Droplet Proteins in Liver

Area of Science:

• Metabolic disease research
• Molecular biology
• Pharmacology

Background:

• Peroxisome proliferator-activated receptor (PPAR) agonists are crucial for managing hyperglycemia and type 2 diabetes, yet their precise mechanisms remain under investigation.
• Lipid droplet-associated proteins FSP27/CIDEC and LSDP5, regulated by PPARγ and PPARα, are implicated in hepatic steatosis and insulin sensitivity.

Purpose of the Study:

• To investigate the expression of FSP27/CIDEC and LSDP5 in response to high-fat diets (HFD) and PPAR agonist treatment.
• To explore the regulatory role of PPAR agonists, specifically fenofibrate and pioglitazone, on these proteins in diet-induced obesity models.

Main Methods:

• Mice with diet-induced obesity were treated with fenofibrate (PPARα agonist) or pioglitazone (PPARγ agonist).
• Liver tissues from treated mice, db/db diabetic mice, and humans were analyzed for FSP27/CIDEC and LSDP5 expression.
• Hepatic triglyceride (TG) content was measured.

Main Results:

• FSP27/CIDEC was expressed in mouse and human livers, with upregulation observed in obese mice.
• Fenofibrate treatment significantly decreased hepatic TG content and FSP27/CIDEC protein levels in HFD-fed mice.
• LSDP5 was not detected in mice but was highly expressed in human livers, particularly in cases of fatty liver.

Conclusions:

• Fenofibrate effectively reduces hepatic TG content and FSP27/CIDEC expression in HFD-fed mice.
• These findings suggest a potential therapeutic role for fenofibrate in ameliorating hepatic steatosis.
• Differential expression of LSDP5 between mice and humans warrants further investigation in the context of fatty liver disease.